Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW642444H versus salmeterol and placebo in moderate COPD
2006-004033-15Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilanterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoints: Safety and tolerability endpoints and Pharmacodynamic endpoints. Started Sep 2006; status: completed.
02
Drugs
vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-004033-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004033-15.